NCT01757795View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of SP-8203

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 23, 2013

Primary Completion Date

March 11, 2015

Study Completion Date

March 11, 2015

Conditions
Ischemic Stroke
Interventions
DRUG

SP-8203

SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial

DRUG

Placebo

Placebo will be intravenously administered

Trial Locations (1)

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

NCT01757795 - Safety, Tolerability and Pharmacokinetics of SP-8203 | Biotech Hunter | Biotech Hunter